DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effects of a Whole Body Vibration Training in Patients After Lung Transplantation

Information source: Klinikum Berchtesgadener Land der Schön-Kliniken
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Patients Following Lung Transplantation (Single and Double)

Intervention: Pulmonary rehabilitation + whole body vibration training (Other)

Phase: N/A

Status: Recruiting

Sponsored by: Klinikum Berchtesgadener Land der Schön-Kliniken

Overall contact:
Klaus Kenn, Dr. med., Phone: 0049865293, Ext: 1540, Email: kkenn@schoen-kliniken.de

Summary

Pulmonary rehabilitation has been established as an evidence-based and recommended therapy in patients following lung transplantation. Exercise training has been shown to be a cornerstone of an inpatient rehabilitation program to reduce muscle dysfunction and improve exercise performance. In our study we will investigate the benefit of a whole body vibration training in addition to a standard pulmonary rehabilitation program that includes endurance and strength training. We will include a total of 140 patients (70 patients < 1 year after lung Transplantation and 70 patients > 1 year after lung Transplantation). Our hypothesis is that an addtitional whole body vibration training produces a greater benefit to exercise capacity in lung transplantat patients (LTx).

Clinical Details

Official title: Effects of a Whole Body Vibration Training on the Exercise Performance in Patients After Lung Transplantation

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: change in 6-minute walking distance

Secondary outcome:

change in Wmax

change in Fmax

change in fibre cross sectional area

change in chair rise time

change in quality of life

change in body cell mass

change in IGF-1

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- participation in an inpatient rehabilitation program

- double or single lung transplantation due to chronic obstructive pulmonary disease,

Alpha-1-antitrypsine deficiency, interstitial lung disease Exclusion Criteria:

- severe exacerbation in the last 4 weeks with the necessity of delivering antibiotics/

corticosteroids

- non-compliance

Locations and Contacts

Klaus Kenn, Dr. med., Phone: 0049865293, Ext: 1540, Email: kkenn@schoen-kliniken.de

Schön Klinik Berchtesgadener Land, Schönau am Königssee 83471, Germany; Recruiting
Inga Heinzelmann, MSc, Sub-Investigator
Rainer Glöckl, MSc, Sub-Investigator
Additional Information

Starting date: January 2012
Last updated: December 12, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017